BIO-TECHNE (NASDAQ:TECH) and Sangamo Therapeutics (NASDAQ:SGMO) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, risk, analyst recommendations, earnings and institutional ownership.


This table compares BIO-TECHNE and Sangamo Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
BIO-TECHNE 19.50% 14.64% 9.53%
Sangamo Therapeutics -105.65% -26.36% -17.00%

Earnings & Valuation

This table compares BIO-TECHNE and Sangamo Therapeutics’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
BIO-TECHNE $642.99 million 11.97 $126.15 million $4.07 50.08
Sangamo Therapeutics $36.57 million 46.98 -$54.56 million ($0.70) -24.14

BIO-TECHNE has higher revenue and earnings than Sangamo Therapeutics. Sangamo Therapeutics is trading at a lower price-to-earnings ratio than BIO-TECHNE, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations and price targets for BIO-TECHNE and Sangamo Therapeutics, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BIO-TECHNE 0 1 5 0 2.83
Sangamo Therapeutics 0 1 5 0 2.83

BIO-TECHNE currently has a consensus target price of $191.83, indicating a potential downside of 5.89%. Sangamo Therapeutics has a consensus target price of $21.40, indicating a potential upside of 26.63%. Given Sangamo Therapeutics’ higher probable upside, analysts plainly believe Sangamo Therapeutics is more favorable than BIO-TECHNE.

Institutional and Insider Ownership

94.3% of BIO-TECHNE shares are held by institutional investors. Comparatively, 63.8% of Sangamo Therapeutics shares are held by institutional investors. 3.8% of BIO-TECHNE shares are held by company insiders. Comparatively, 1.2% of Sangamo Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Volatility and Risk

BIO-TECHNE has a beta of 0.88, meaning that its stock price is 12% less volatile than the S&P 500. Comparatively, Sangamo Therapeutics has a beta of 2.95, meaning that its stock price is 195% more volatile than the S&P 500.


BIO-TECHNE pays an annual dividend of $1.28 per share and has a dividend yield of 0.6%. Sangamo Therapeutics does not pay a dividend. BIO-TECHNE pays out 31.4% of its earnings in the form of a dividend.


BIO-TECHNE beats Sangamo Therapeutics on 10 of the 14 factors compared between the two stocks.


Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells biotechnology reagents, instruments, and clinical diagnostic controls worldwide. It operates in three segments: Biotechnology, Protein Platforms, and Diagnostics. The Biotechnology segment offers specialized proteins, such as cytokines and growth factors, immunoassays, antibodies, and related reagents to the biotechnology research community; and in situ hybridization, media, and other cell culture products and reagents. It also provides various products, which serves as predictive biomarkers and therapeutic targets for various human diseases and conditions, such as cancer, autoimmunity, diabetes, hypertension, obesity, inflammation, neurological disorders, and kidney failure. The Protein Platforms segment offers Biologics tools for researchers to interrogate protein purity and identify contaminants during the development and production of biologics; Western blot, an assay for protein analysis and identification; SimplePlex platform, an enzyme-linked immunosorbent assay for use in research and clinical diagnostics; and Single Cell Western platform to elucidate the properties of individual cells to understand cell behavior. The Diagnostics segment provides blood chemistry and gas quality controls, hematology instrument controls, diagnostic immunoassays, and other bulk and custom reagents for the in vitro diagnostic market. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc. focuses on translating science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation. The ZFPs could be engineered to make ZFP nucleases (ZFNs), proteins that could be used to modify DNA sequences by adding or knocking out specific genes; and ZFP transcription factors (ZFP TFs), proteins that can be used to turn genes on or off. Its therapeutic products include SB-728-T, a ZFN-mediated autologous T-cell product for human immunodeficiency virus and acquired immunodeficiency syndrome (HIV/AIDS), which is in Phase II and I clinical trials; and SB-728-HSPC that is in Phase I/II clinical trials for HIV/AIDS. The company also engages in Phase I/II studies of in vivo genome editing applications of ZFP Therapeutics for Hemophilia B, Hemophilia A, and Mucopolysaccharidosis I (MPS) and MPS II, which are lysosomal storage disorder (LSD); preclinical programs in other LSDs; and research stage programs in central nervous system disorders and cancer immunotherapies. It has collaborative partnerships with Biogen Inc. to develop therapeutic genome editing products in hemoglobinopathies; and Shire International GmbH to develop preclinical development program in Huntington's disease, as well as license agreements with Sigma-Aldrich Corporation to develop laboratory research reagents and Dow AgroSciences, LLC to modify the protein expression of plant cells and plants. The company also has a research collaboration and license agreement with Pfizer Inc; and collaboration with Kite for developing ex vivo cell therapies in oncology. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was founded in 1995 and is headquartered in Richmond, California.

Receive News & Ratings for BIO-TECHNE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIO-TECHNE and related companies with's FREE daily email newsletter.